Thanks for signing up for DividendStocks.com! It's the daily newsletter built for dividend and income investors. Before we can begin sending your daily updates, there’s one quick step left. Please confirm your subscription using the link below so our emails reach your inbox. Click Here to Confirm Your Subscription to DividendStocks.com Here’s a small glimpse of what you’ll get access to: Dividend Stock Ideas — Each newsletter features dividend stocks with high yields, sustainable payouts, and strong growth potential. Ex-Dividend Stocks — Want to capture upcoming dividend payouts? Find out which stocks are going ex-dividend this week. Market News and Events — Stay in the loop on the latest developments impacting popular dividend names like AT&T, Exxon Mobil, IBM, Procter & Gamble, and Verizon. Bonus: As a thank-you for confirming, you’ll also receive a free PDF copy of Automatic Income, our popular guide to building wealth through dividend investing. Let’s get your dividend journey started! Discover Top Income-Generating Stocks Here See you in your inbox soon,
The DividendStocks.com Team P.S. Don’t miss out click here to verify your subscription and secure your daily dividend insights and your free investing guide!
Wednesday's Exclusive Story The 3 Penny Stocks You Swore You'd Never Buy (But You'll Check Anyway)Submitted by Chris Markoch. First Published: 1/18/2026. 
What You Need to Know - Vaxart is a clinical-stage biotech developing oral vaccines that could transform global immunization if its platform proves effective.
- Microvision develops cost-effective lidar technology for autonomous vehicles, with upside tied to industry adoption and potential partnerships.
- Datavault AI focuses on monetizing digital data through AI and blockchain tools, offering speculative exposure to the emerging data-as-an-asset theme.
Penny stocks attract speculative investors seeking high-risk, high-reward opportunities. That often means targeting companies with disruptive technologies, involvement in emerging trends, or compelling turnaround stories. Many of these firms will never survive or scale, but if one succeeds, investors can see impressive returns. For investors who believe strength lies in numbers, MarketBeat provides a tool that lists the 100 Most Popular Penny Stocks, ranked by the number of MarketBeat subscribers following each company. While that's no guarantee of success, it can help build conviction in a stock's potential. Recent algorithm alerts have flagged stocks like Nuburu, MSS, and Rebel Holdings ahead of sharp moves — including triple-digit gains in a short time frame. These signals all came from Tim Bohen's new system, called The Monday Algo, which scans the market each week for early breakout setups.
Now, the algorithm is highlighting a new low-priced stock heading into Monday. While no trade is guaranteed, Tim is breaking down why this setup stands out — and how he and his students approach these Monday momentum opportunities. See the latest Monday Algo setup here Some investors define a penny stock as any equity trading for $5 or less. This screener uses the traditional definition — stocks trading below $1. These names are highly volatile; conduct your own research and understand your risk tolerance before taking a position. Vaxart: A Potential Game-Changer for Global Immunization Efforts Vaxart Inc. (NASDAQ: VXRT) is a clinical-stage biotechnology company developing oral vaccines for infectious diseases, including influenza, norovirus, and COVID-19. Unlike traditional injectable vaccines, Vaxart's tablet-based platform aims to simplify distribution and improve global accessibility. The bull case for Vaxart centers on its innovative delivery approach. If the company can secure FDA approval and scale successfully, its oral vaccines could reduce logistical barriers to mass immunization campaigns and create significant licensing or partnership opportunities. Positive trial results or a commercial collaboration could dramatically shift sentiment and valuation from its current low base. Clinical risk remains the primary challenge. Vaxart has not yet brought a product to market, and vaccine development is costly and unpredictable. Competition from established players with larger R&D budgets also limits visibility. For now, Vaxart is best viewed as a long-term, speculative bet on platform validation rather than near-term profitability. MarketBeat's analyst ratings show only a single analyst covering the stock, which may raise a red flag for some investors. Institutional ownership is just 18%. On the positive side, short interest is approximately 2%, which may limit some volatility stemming from heavy shorting. Microvision: Developing Cost-Effective LiDAR Units For Autonomous Driving Microvision Inc. (NASDAQ: MVIS) develops LiDAR (light detection and ranging) sensors for autonomous vehicles, smart infrastructure, and industrial sensing. Its hardware and software enable precise 3D mapping required for self-driving and advanced driver-assistance systems (ADAS). Microvision focuses on compact, cost-effective LiDAR units that could appeal to automakers seeking scalable sensor solutions. The bull case for Microvision rests on two factors: the continued push toward vehicle automation and the potential for partnerships with major automotive manufacturers. If the company can demonstrate superior performance or cost advantages, it could secure supply agreements or licensing deals that meaningfully improve revenue visibility. Microvision's technology could also find applications beyond vehicles — in robotics and smart cities — adding optionality to its growth story. Despite the promise, Microvision faces stiff competition from LiDAR specialists like Luminar (NASDAQ: LAZR), Innoviz (NASDAQ: INVZ), and Ouster (NYSE: OUST). The path to profitability is uncertain, and repeated delays in commercial adoption of LiDAR continue to frustrate investors. MVIS is covered by three analysts and has a consensus price target of $2.50, a 169% gain from its Jan. 15 closing price. However, Microvision has relatively low institutional ownership (around 30%) and high short interest (about 21%). Long-term investors should be prepared for significant volatility. Datavault AI: Trying to Democratize Data Ownership Datavault AI Inc. (NASDAQ: DVLT) operates at the intersection of artificial intelligence, data monetization, and digital asset management. The company helps organizations turn raw data into tradable, revenue-generating assets through its patented Datavault platform. By combining AI, blockchain, and analytics tools, Datavault AI aims to democratize data ownership and unlock monetization opportunities that traditional systems often overlook. The bullish thesis for Datavault AI rests on its niche focus and scalability potential. As data becomes an increasingly valuable commodity, businesses — and potentially individuals — are seeking ways to safely monetize digital information. Datavault's platform could benefit from broader AI adoption and heightened awareness of data sovereignty. Early-stage traction or strategic partnerships could catalyze investor confidence. Still, Datavault AI operates in a highly experimental space. The company's business model is evolving, and its path to meaningful revenue growth remains unproven. Institutions own less than 1% of the stock, and short interest is over 16% as of this writing. Investors considering DVLT should view it as a long-term, speculative position based on belief in data-as-an-asset innovation rather than on near-term earnings potential.
| 
